Ursula Aho Fält

Ursula Aho Fält

Auto-generated profile, based on publicly available information

Ursula Aho Fält

Surgery Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
RARoland Andersson
Roland Andersson
UAUrsula Aho
Ursula Aho
BNBo I. Nilsson
Bo I. Nilsson
Godefridus J. PetersGodefridus J. Peters
Godefridus J. Peters
Marçal Pastor-AngladaMarçal Pastor-Anglada
Marçal Pastor-Anglada
MSMarit L. Sandvold
Marit L. Sandvold
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.

12 June 2008 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
ABA. Bartosch‐Härlid
A. Bartosch‐Härlid
BAB. Andersson
B. Andersson
UAU. Aho
U. Aho
JNJ. Nilsson
J. Nilsson
RAR. Andersson
R. Andersson

5 November 2020 in Colorectal Disease
Verified
Journal Article
Open access
PDF file
UFUrsula Aho Fält
Ursula Aho Fält
AZAntoni Zawadzki
Antoni Zawadzki
MSMarianne Starck
Marianne Starck
MBMåns Bohe
Måns Bohe
LJLouis B. Johnson
Louis B. Johnson
Aim: To evaluate the long‐term success rate of treatment with the Surgisis® (Biodesign®) anal fistula plug for complex anal fistulas, assess fistula plug failure over time and compare success rates for fistula plug between a group of patients with cryptoglandular fistula and another group with Crohn's fistula.Method: This is a single‐centre study of consecutive patients treated with the Surgisis® (Biodesign®) anal fistula plug between May 2006 and October 2009. All patients had complex anal fistulas in need of surgical treatment. The patients were assessed preoperatively by physical examination and three‐dimensional (3D) endoanal ultrasound, and treated with a loose seton. Postoperative assessment by clinical examination and 3D endoanal ultrasound was performed at 2 weeks, 3 months and 6–12 months. Long‐term follow‐up was carried out in 2017 using a questionnaire, and clinical examination combined with 3D endoanal ultrasound was performed if the questionnaire indicated any signs of fistula recurrence.Results: A total of 95 patients were included; 30 had quiescent Crohn's disease. Overall, 151 plug procedures were performed. Long‐term follow‐up was undertaken in 90 (95%) patients; the results showed that after a median period of 110 months, the overall healing rate after one to five plug procedures was 38%. No statistically significant difference in success rate was found between the cryptoglandular fistula group and the Crohn's fistula group (P = 0.37). No further healing was observed after the use of three plugs.Conclusion: Considering its low morbidity in a complex disease with high recurrence rates over time, the anal fistula plug may still be considered as one of the first‐line treatments for patients with complex anal fistulas.

10 April 2019 in Techniques in Coloproctology
Verified
Journal Article
Open access
PDF file
UFUrsula Aho Fält
Ursula Aho Fält
MLMartin Lindsten
Martin Lindsten
SSSara Strandberg
Sara Strandberg
MDMari Dahlberg
Mari Dahlberg
SBSalma Butt
Salma Butt
LJLouis Banka Johnson
Louis Banka Johnson
The aim of the present study was to evaluate percutaneous tibial nerve stimulation (PTNS) for treatment resistant chronic anal fissure.

1 January 2007 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
UAUrsula Aho
Ursula Aho
XZXia Zhao
Xia Zhao
MLMatthias Löhr
Matthias Löhr
RARoland Andersson
Roland Andersson

18 May 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Open access
UFUrsula Aho Fält
Ursula Aho Fält
AZAntoni Zawadzki
Antoni Zawadzki
MSMarianne Starck
Marianne Starck
MBMåns Bohe
Måns Bohe
SRSara Regnér
Sara Regnér
LJLouis B. Johnson
Louis B. Johnson
ObjectivesTo explore the utilization of three-dimensional (3D) endoanal ultrasound (EAUS) for the follow-up of the anal fistula plug (AFP), describe morphological findings in postoperative 3D EAUS, and evaluate if postoperative 3D EAUS combined with clinical symptoms can predict AFP failure.Materials and methodsA retrospective analysis of 3D EAUS examinations performed during a single-centre study of prospectively included consecutive patients treated with the AFP between May 2006 and October 2009. Postoperative assessment by clinical examination and 3D EAUS was performed at 2 weeks, 3 months and 6-12 months ("late control"). Long-term follow-up was carried out in 2017. The 3D EAUS examinations were blinded and analysed by two observers using a protocol with defined relevant findings for different follow-up time points.ResultsA total of 95 patients with a total of 151 AFP procedures were included. Long-term follow-up was completed in 90 (95%) patients. Inflammation at 3 months, gas in fistula and visible fistula at 3 months and at late control, were statistically significant 3D EAUS findings for AFP failure. The combination of gas in fistula and clinical finding of fluid discharge through the external fistula opening 3 months postoperatively was statistically significant (p < 0.001) for AFP failure with 91% sensitivity and 79% specificity. The positive predictive value was 91%, while the negative predictive value was 79%.Conclusions3D EAUS may be utilized for the follow-up of AFP treatment. Postoperative 3D EAUS at 3 months or later, especially if combined with clinical symptoms, can be used to predict long-term AFP failure.ClinicalTrials.gov identifier NCT03961984